摘要
目的探讨聚乙二醇干扰素α-2α延长疗程治疗HBeAg阳性慢性乙型肝炎（CHB）患者的临床疗效。方法对63例HBeAg阳性CHB患者接受聚乙二醇干扰素（PEG—IFNα-2α，上海罗氏制药有限公司生产）180μg，每周1次，皮下注射。将他们随机分为两组，常规治疗组（I组）31例，延长治疗组（Ⅱ组）32例。常规治疗组用药48周，延长治疗组用药至72周。分别于治疗结束后对两组患者的临床疗效进行评估。结果治疗结束后延长治疗组的病毒学应答率（62．5％）明显高于常规治疗组（43．8％），两组比较差异有统计学意义（P〈0．05）；延长治疗组在HBV—DNA水平下降幅度及HBsAg水平下降幅度上也明显高于常规治疗组，两组比较差异有统计学意义（P〈0．05）；延长治疗组的HBeAg血清学转换率和HBsAg消失率（37．5％，3．2％）虽高于常规治疗组（29．0％，0％），但两组比较差异无统计学意义。结论聚乙二醇干扰素α-2α对HBeAg阳性慢性乙型肝炎延长疗程至72周的临床疗效优于常规48周疗程。
Objective To evaluate antiviral effects of therapy by prolonging the duration of Peg- IFNα-2α on HBeAg positive chronic hepatitis B （CHB） patients. Methods Sixty-three CHB with HBeAg positive patients were enrolled to receive the treatment with Peg-IFNα-2α 180μg subcutaneous injection once weekly. The patients were randomized into two groups： group I （31 cases） conventional treatment to 48 weeks, group Ⅱ （32 cases）, extend the treatment to 72 weeks. Clinical antiviral effect was assessed at the end of treatment in two groups. Results At the end of treatment, patients in group Ⅱ had significantly higher virologic response rate （62. 5 % ） than patients in group I （43.8 % ）, which was statistically significant （P 〈 0.05 ）. The mean reductions of HBV-DNA and HBsAg were significantly higher than that in group I , which were also statistically significant （P 〈 0. 05 ）. Patients in group II had higher HBeAg seroconversion and HBsAg loss rates（37.5% , 3.2% ） , But compared with group I （29.0%, 0 ）. There was no statistical difference （P 〉 0.05 ）. Conclusions Clinical antiviral effects of therapy by prolonging the duration to 72 weeks of Peg-IFNα-2α on HBeAg positive CHB patients were higher than conventional treatment to 48 weeks.
出处
《中国实用医刊》
2012年第20期30-31,共2页
Chinese Journal of Practical Medicine
